Maha Hussain, MD, on Prostate Cancer: Results From the PROSPER Trial
2018 Genitourinary Cancers Symposium
Maha Hussain, MD, of Northwestern University, discusses phase III findings on enzalutamide in men with nonmetastatic castration-resistant prostate cancer (Abstract 3).
Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abstract 413).
Joaquim Bellmunt, MD, PhD, of the Dana-Farber Cancer Institute, discusses phase III 2-year follow-up findings on pembrolizumab vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (Abstract 410).
Eric J. Small, MD, of the University of California, San Francisco, discusses phase III findings on apalutamide vs placebo in patients with nonmetastatic castration-resistant prostate cancer (Abstract 161).
Jeffrey M. Holzbeierlein, MD, of the University of Kansas Medical Center, summarizes key abstracts on long-term sexual function in germ cell tumor survivors, sentinel node biopsy in clinical stage I testicular cancer, the impact of Medicaid expansion on diagnosis and management of patients with testicular cancer, and comparative genomic profiling of refractory/metastatic penile and nonpenile cutaneous squamous cell carcinoma (Abstracts 549-552).
Robert G. Bristow, MD, PhD, of Manchester Cancer Research Centre, discusses germline and somatic mutations; new ways to generate biomarkers that may describe tumor complexity; and how, in the future, this information may help triage patients with aggressive prostate tumors to intensified treatments.